Merck KGaA (OTCMKTS:MKGAY) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Merck KGaA (OTCMKTS:MKGAYGet Rating) have earned an average rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $252.50.

MKGAY has been the topic of a number of recent research reports. UBS Group raised Merck KGaA from a “sell” rating to a “neutral” rating in a report on Monday, February 28th. JPMorgan Chase & Co. lowered their price objective on Merck KGaA from €270.00 ($287.23) to €250.00 ($265.96) and set an “overweight” rating for the company in a research note on Monday, March 14th.

Shares of MKGAY remained flat at $$38.36 during trading hours on Friday. Merck KGaA has a 1 year low of $32.53 and a 1 year high of $42.02. The company’s 50-day moving average is $38.36 and its two-hundred day moving average is $38.36.

Merck KGaA Company Profile (Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

Featured Stories

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with's FREE daily email newsletter.